Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference

Rhea-AI Summary

Kiniksa Pharmaceuticals (KNSA) will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 8:50 a.m. ET. A live webcast of the presentation can be accessed on the company's website, with a replay available for 14 days post-conference.

Kiniksa focuses on biopharmaceuticals, developing treatments for diseases with unmet needs. Its pipeline includes rilonacept, mavrilimumab, vixarelimab, and KPL-404, which target immunological pathways and aim to address underserved conditions.

News Market Reaction – KNSA

+9.87%

+9.87% Session move

In the trading session that priced this news, KNSA gained 9.87%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAMILTON, Bermuda, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1^st, 2020 at 8:50 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These pipeline assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

Every Second Counts!™ Kiniksa Investor and Media Contact Mark Ragosa (781) 430-8289 mragosa@kiniksa.com

FAQ

When is Kiniksa's presentation at the HealthCONx Conference?

Kiniksa will present on December 1, 2020, at 8:50 a.m. Eastern Time.

How can I watch Kiniksa's presentation live?

The live webcast can be accessed through the Investors & Media section of Kiniksa's website.

Will there be a replay of Kiniksa's presentation?

Yes, a replay will be available on Kiniksa's website for 14 days following the conference.

What is the focus of Kiniksa Pharmaceuticals?

Kiniksa focuses on discovering and developing therapeutic medicines for debilitating diseases with significant unmet medical needs.

What product candidates does Kiniksa have in its pipeline?

Kiniksa's pipeline includes rilonacept, mavrilimumab, vixarelimab, and KPL-404.